

**Saskatoon Health Region ANTIBIOTIC SUSCEPTIBILITY TESTS**  
**ADULT OUTPATIENTS - Urinary Isolates**  
**January 1, 2016 - December 31, 2016**

**Outpatients – % Susceptible**

	# Isolates tested	Penicillin PO/IV	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cephalexin	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftazidime	Meropenem	Ertapenem	Clindamycin	Aztreomycin	Erythromycin	Tetracycline/Doxycycline	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Nitrofurantoin (urine only)	Gentamicin <sup>3</sup>	Tobramycin	Vancamycin	
<b>GRAM-NEGATIVE BACTERIA</b>																										
<i>Escherichia coli</i> <sup>1</sup>	11671	59		87	97		88	95		94	95	100	100					85		79	98	93	94			
<i>Enterobacter aerogenes</i> <sup>2</sup>	121	30		R	92		32	R		89	88	100	100					100		99	28	100	100			
<i>Enterobacter cloacae</i> <sup>2</sup>	241	R		R	86		R	R		83	83	100	92					98		90	47	97	97			
<i>Klebsiella pneumoniae</i> <sup>1</sup>	1463	R		96	96		94	95		96	96	100	100					97		93	62	98	98			
<i>Klebsiella oxytoca</i>	315	R		91	91		45	98		94	100	100	100					99		91	92	98	98			
<i>Pseudomonas aeruginosa</i> <sup>2</sup>	254				98						97	96						91				96	97			
<i>Morganella morganii</i> <sup>2</sup>	58	R		R	100		R	43		95	97	100	100					95		81	R	88	97			
<i>Proteus mirabilis</i>	450	84		97	100		89	99		98	99	100	100					97		90	R	96	98			
<i>Citrobacter freundii</i> <sup>2</sup>	139	R		66	92		R	R		89	89	100	99					98		88	96	98	99			
<i>Citrobacter koseri</i> <sup>2</sup>	157	R		99	100		97	97		99	98	100	100					99		100	95	99	99			
<i>Serratia marcescens</i> <sup>2</sup>	40	R		28	100		R	30		100	97	100	100					93		100	R	98	98			

	# Isolates tested	Penicillin PO/IV	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cephalexin	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftazidime	Meropenem	Ertapenem	Clindamycin	Aztreomycin	Erythromycin	Tetracycline/Doxycycline	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Nitrofurantoin (urine only)	Gentamicin <sup>3</sup>	Tobramycin	Vancamycin	
<b>GRAM-POSITIVE BACTERIA</b>																										
<i>Staphylococcus aureus</i> , all																										
- methicillin-susceptible (MSSA)	218			100												84		83	95	91	93	96	100	99		100
- methicillin-resistant (MRSA)	30	R	R	R	R	R	R	R	R	R	R	R	R	R	63		47	97	57	57	100	97	100		100	
<i>Enterococcus faecalis</i> , urine	1563	99					R	R	R	R	R	R	R				R	R	85	87		99			100	
<i>Enterococcus faecium</i> , urine	97	R					R	R	R	R	R	R	R				R	60	R	R		38			95	

R - intrinsically resistant or less than 25% empiric susceptibility

‡ Isolates containing less than 30 reported specimens should be interpreted using presented data ALONG WITH clinical judgement and/or input from infectious diseases service

<sup>1</sup> 4.3 % of *E.coli* (n = 505) and 3.6 % of *K.pneumoniae* (n= 52) were +ESBL (extended spectrum beta-lactamase)

<sup>2</sup> these organisms may produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility

<sup>3</sup> susceptibility to gentamicin in gram positive organisms refers to combination synergy treatment only